Open an account

InterCure

INCR · TEL

$4.43−$0.03 (−0.67%)TodayMarket closed ·
Prev close $4.46

About INCR

InterCure Ltd. engages in the provision of business of medical cannabis and biomedicine. Thorugh its wholly owned subsidiary Canndoc the Company operates as licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products.

Employees
320
Headquarters
Herzliya
Listed
Jul 26, 2007
Sector
Health Care
Industry
Pharmaceuticals
Website
intercure.co

INCR key statistics

Market cap
169.16M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
5.07K
Volume
2.54K
Open price
$4.59
High today
$4.76
Low today
$4.43
52 Week high
$7.90
52 Week low
$3.40

InterCure (INCR) at a glance

As of Oct 20, 2026, InterCure (INCR) shares are priced at $4.43, giving the company a market cap of 169.16M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $4.43 and $4.76. The current price is 0.0% above the day's low and 6.9% below its high.

Volume so far is 2.54K shares, below the average of 5.07K shares a day.

Over the past year InterCure has ranged from $3.40 to $7.90, and now sits 23% of the way up that range.

InterCure met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY23 it reported $0.525 per share against an estimate of $0.408.

INCR earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 42.4% on average.

  1. Q2 FY21: reported $0.60 per share against an estimate of $0.7141
  2. Q3 FY21: reported -$0.15 per share against an estimate of $0.765
  3. Q4 FY21: reported -$0.30 per share against an estimate of $0.714
  4. Q1 FY22: reported $1.80 per share against an estimate of $0.918
  5. Q3 FY22: reported $0.80 per share against an estimate of $1.27
  6. Q4 FY22: reported $0.9416 per share against an estimate of $0.918
  7. Q1 FY23: reported $0.025 per share against an estimate of $0.204
  8. Q2 FY23: reported $0.525 per share against an estimate of $0.408

INCR news

  • Vishaal Sanjay

    Trump's Marijuana Reclassification Looks Set To Send This Cannabis ETF Soaring: Big Surge In Momentum

  • Press releaseGlobe Newswire

    InterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical Innovation

  • Nabaparna Bhattacharya

    InterCure Enters Premium US Cannabis Market With ISHI Deal

  • Press releaseGlobe Newswire

    InterCure Announces Strategic Acquisition of ISHI, Unlocking Access to Premium U.S. Cannabis Technology and Brands

  • Press releasePRNewswire

    InterCure Announces FY2024 Results and Provides Q1 2025 Update: Revenue of NIS 239 Million and Adjusted EBITDA of NIS 24 Million, Strong Start to 2025

  • Press releasePRNewswire

    InterCure Names Alexander Rabinovich as Chairman Replacing Ehud Barak

  • Press releasePRNewswire

    InterCure has Secured Funding of NIS 66M to support the recovery of Nir Oz Facility

  • Nicolás Jose Rodriguez

    Are Investors Missing The Forest? 35% Stock Drop Masks The International Potential Of This Weed Company

Similar companies

Companies in the same industry as InterCure

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.